Delivery Order SPE2DR25D1002-SPE2DR26FGJ2D
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for HYPERRAB 300 Unit/mL Vial 5mL at a ceiling value of $10,686.55 under a firm fixed price contract. This delivery order represents a non-competitive, competitively awarded procurement with an ultimate completion date of September 24, 2025. The pharmaceutical product will be delivered to the contractor's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on September 21, 2025, for the supply of HYPERRAB 300 Unit/ML Vial pharmaceutical product. This firm fixed-price delivery order carries a ceiling value of $3,465.10 with an ultimate completion date of October 10, 2025, and was awarded without set-aside designations through competitive procedures. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a $17,908 delivery order to AmerisourceBergen Drug Corp on September 22, 2025, for the supply of HYPERRAB 300 Unit/ML vial in 5ML quantities. This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of October 14, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite...
- The Defense Logistics Agency awarded a $1,790.80 delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of HYPERRAB 300 Unit/ML Vial 5ML, with completion targeted for October 2, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a continuation of the contractor's pharmaceutical supply services to the federal government. The place of performance is located in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a $14,053.14 firm fixed price delivery order to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML vials (5ML) on May 30, 2025, with an ultimate completion date of June 23, 2025. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The award was competitively awarded without set-aside designation and will be...
- The Defense Logistics Agency awarded a delivery order valued at $1,341.84 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML vials, with an ultimate completion date of December 23, 2025. This is a firm fixed-price contract with no set-aside designation, representing a competitively awarded procurement. The contract work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $1,386.04 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML vials. This firm fixed-price delivery order was competitively awarded without set-aside designation and is scheduled for completion by August 15, 2025. AmerisourceBergen will perform the work at its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $3,354.60 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/mL vials, with performance in Conshohocken, Pennsylvania and an ultimate completion date of December 22, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and represents a continuation of AmerisourceBergen's extensive role as a critical pharmaceutical supplier to federal medical procurement programs, particularly for...
- The Defense Logistics Agency awarded a $5,053.44 delivery order to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/mL vial on December 10, 2025, with an ultimate completion date of January 2, 2026. This is a firm fixed price, non-set-aside contract to be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for HYPERRAB 300 Unit/ml Vial pharmaceutical products with a ceiling value of $2,079.06 and a firm fixed price structure. The contract is set for ultimate completion by August 26, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- SPE2DR25D1002Indefinite Delivery Contract
- SPE2DR25D1002-SPE2DR26FGJ2DDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 30, 2025, for the supply of HYPERRAB 300 Unit/mL Vial 5mL, with a ceiling value of $1,733.74 and an ultimate completion date of November 21, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation to AmerisourceBergen's Corporate Office division, headquartered in Conshohocken, Pennsylvania. The order represents a child contract under the company's broader relationship with the federal medical supply chain. This delivery order is issued under AmerisourceBergen Drug Corp's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the supply of a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. AmerisourceBergen's extensive federal contract portfolio demonstrates its critical role as a major pharmaceutical distributor serving the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems through flexible contract vehicles designed to meet diverse medical procurement requirements across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 10/30/25 |